A-Bio Materials, a Seoul-based developer of exosome-derived biomaterials, has closed a Series C financing with strategic participation from Shinsegae International and the Shinsegae Group’s venture arm, SIGNITE, the company announced. The investment is earmarked to accelerate the company’s move into higher-margin medical devices and to underpin a planned public listing on Korea’s KOSDAQ market.
Founded in 2020, A-Bio Materials designs and manufactures exosome and PDRN (polydeoxyribonucleotide) ingredients derived from a range of biological sources, including human cells, plants and microbes. Exosomes — nanoscale, membrane-bound extracellular vesicles roughly 30 to 150 nanometers in diameter — are being explored for their roles in intercellular signaling and for biologic activities such as tissue regeneration and inflammation control. The company says it now produces 39 distinct exosome and PDRN raw materials and has built a portfolio of intellectual property and peer-reviewed research to support its technology claims.
A-Bio lists proprietary purification and culture processes — marketed under the names Exo-traction®, Celltivation and Escentraction — as the technical backbone that enables its commercial production. The company also reported having secured 55 patents and publishing 34 papers in SCIE-indexed journals, figures it attributes to strengthening its technology credibility.
Shinsegae International’s investment is consistent with the retailer’s broader strategy to reinforce a “high-performance beauty” portfolio centered on innovation and proprietary ingredients. Shinsegae’s beauty division — the company said — accounted for roughly 37 percent of the retailer’s first-half revenue this year and has emerged as a key growth pillar.
A-Bio intends to deploy the new capital primarily to expand its medical-device operations. The company is preparing regulatory submissions for higher-risk, class-4 medical devices and plans to build a Good Manufacturing Practice (GMP) facility to support device production and quality systems. Company materials describe the capital as critical to “product line enhancement” and to positioning A-Bio’s exosome platforms for clinical and device-adjacent applications.
Management has disclosed a timetable that connects near-term commercial scaling with a longer-term capital markets objective: A-Bio is targeting a KOSDAQ listing in 2027. As part of its growth roadmap the company has set medium-term financial targets, including achieving 30 billion won in revenue and 10 billion won in operating profit by 2026.
International expansion is already under way. A-Bio has established a U.S. subsidiary in California to strengthen access to North American buyers, and it said it is promoting its exosome ingredients at global beauty and medical trade shows. The company also indicated ongoing business discussions in Europe, the Middle East and Southeast Asia.
Executives framed the Shinsegae investment as validation of A-Bio’s strategy to move beyond contract manufacturing toward higher-value, bio-enabled beauty and medical aesthetics solutions. The pairing of a major retail and brand operator with an ingredient and biologics developer underscores a broader industry trend in which retailers and brand owners seek proprietary supply chains and differentiated ingredients.
The information provided to The New York Times for this article was supplied by A-Bio Materials and Shinsegae International. The reporting here is restricted to the facts and projections disclosed by those parties.
Copyright ⓒ 센머니 무단 전재 및 재배포 금지
본 콘텐츠는 뉴스픽 파트너스에서 공유된 콘텐츠입니다.
